AzTrials
AzTrials

PneumoniaPneumOldCTNCT02467192

The Place of Imaging and Microbiology in the Diagnosis of Pneumonia in the Elderly

A study testing Low dose CT in people with Pneumonia, run by University Hospital, Geneva at 1 site in Switzerland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Diagnosis of pneumonia in the elderly is difficult because of the poor sensitivity and specificity of clinical signs as well as images from chest radiography (RT). New diagnostic tools such as thoracic low-dose computed tomography (CT), which exposes the patient to a weak dose of irradiation, could improve diagnosis. Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Pneumonia
What is being tested?
Low dose CT
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
203 participants
Where
1 siteSwitzerland
Study dates
1 May 2015to 1 May 2017
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • Patients above 65 years old
  • AND at least one infectious sign: T° >38°C or <35°C; C-reactive protein (CRP) >10 mg/L; leucocytes >10,000/mL with >85% polynuclear neutrophils or left deviation,
  • AND at least one respiratory sign: cough; purulent sputum; chest pain; localized crackles; recently appeared dyspnea; oxygen saturation (SpO2) <90%; respiratory frequency >20/min,
  • AND who will be prescribed antimicrobial therapy for suspicion of low respiratory tract infection,
  • AND who will give consent himself or through his support person.

Who cannot join

  • Diagnosis of pneumonia in the previous six months,
  • AND/OR more than 48h of antimicrobial treatment given before hospitalization,
  • AND/OR thoracic CT scan performed before hospitalization or inclusion of the patient.
  • Each patient will be included only once.

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • HUG

    Geneva, 1211

Other trials in Switzerland

About this study

Official title: The Place of Imaging and Microbiology in the Diagnosis of Pneumonia in the Elderly: PneumOldCT

Diagnosis of pneumonia in the elderly is difficult because of the poor sensitivity and specificity of clinical signs as well as images from chest radiography (RT). New diagnostic tools such as thoracic low-dose computed tomography (CT), which exposes the patient to a weak dose of irradiation, could improve diagnosis. Moreover, low-dose CT could provide additional accuracy in the etiological clarification of pneumonia in elderly people.

As a first step, the investigators aim to perform a 1 year (12 months of inclusion + 3 months of follow-up) prospective study including the Divisions of Internal Medicine, Rehabilitation, Geriatrics and Radiology of the University Hospitals of Geneva. In this study, patients >65 years old with a clinical suspicion of low respiratory tract infection (LRTI) will be included. They will be prescribed antimicrobial therapy. Both chest radiography and low-dose thoracic CT will be performed within the first 72 hours after admission, as will blood tests and a nasopharyngeal swab.

Read more

The clinician's diagnosis, both before and after the results of the CT, will be compared at the end of the study to the adjudication committee's diagnostic opinion which will have access to all available clinical, laboratory and chest X-ray data and which will be considered the gold standard. At the end of the study, all the CT images will be blind-reviewed by two experts in radiology. The impact of CT scanning in the diagnosis of pneumonia will be assessed, both for its sensitivity and specificity in this population.

During the first 12 months of the study, all patients will undergo a systematic nasopharyngeal swab at admission and at discharge, from which eluates will be conserved. During the next 12 months, virological and bacteriological polymerase chain reactions (PCR) will be performed, using new diagnostic tools, in order to determine the etiological diagnosis in this population and to evaluate the impact of the new tools in the management of pneumonia for this population.

Analysis of these data will allow clinical, radiological and microbiological correlation.

Read the detailed description

The project's principal aim is to assess the impact of low-dose CT scanning versus chest radiography in the diagnosis of pneumonia in elderly patients.

One of the secondary objectives is to estimate sensitivity and specificity of CT scanning in pneumonia diagnosis in the elderly (gold standard: adjudication committee advice).

This prospective study should be considered a preliminary feasibility study in preparation for a future randomized clinical trial comparing patient management, antibiotic prescription and clinical outcomes between one group of patients with LRTI randomized to routine thoracic CT scan and one group randomized to usual care.

The second phase of this study will explore the etiologies of pneumonia in the elderly using new diagnostic tools. This will lead to identify radiological patterns associated with clinical presentation and microbiological results.

Primary objective: to estimate the impact of CT scanning in the diagnosis of pneumonia in elderly patients, in a monocentric study (but within two sites, Service de Médecine Interne Générale and Hôpital des Trois-Chêne).

Secondary objectives: to estimate sensitivity and specificity of CT scanning in pneumonia diagnosis (gold standard: adjudication committee advice), and to identify microbiological etiologies of pneumonia in the elderly.

Study-design: prospective interventional study.

Intervention:

Patients will be managed according to HUG guidelines. Frontal (and lateral if possible) chest radiography (RT) will be interpreted by the physician; he will assess the level of certainty for a diagnosis of pneumonia on a Likert scale, as well as its localization. Subsequently, a thoracic CT scan will be performed within the first 48-72 hours of admission, with conclusion by a radiologist (on a Likert scale). After the CT scan, the physician will get the result and assess a new level of certainty of diagnosis (on a Likert scale). If the clinician changes his therapy, this will be noted on the case report form (CRF).

Patients will undergo two nasopharyngeal swabs (on admission and discharge) for storage in a biobank, and microbiological (bacteriological and viral) PCR will be performed at a later date.

Patients will be followed until day 90. Information concerning rehospitalization and death will be obtained by review of the patient's medical chart and the civil registry.

At the end of the study, chest radiographs (RT) and CT will be blinded-analyzed by two referring radiologists (MS and XM).

An adjudication committee (one internist, one infectiologist, one pneumologist) will review patients' data in order to provide a gold standard diagnosis which will be made according to international guidelines (8, 9): clinical symptoms, recent new abnormalities on chest radiograph and outcome under antimicrobial therapy.

After the end of the clinical study, the virology group will analyze the eluates from the nasopharyngeal swabs using new PCR tests. After completing routine PCR (Adenovirus, Bocavirus, Coronavirus, Enterovirus, Influenza A and B viruses, Parainfluenza virus, Parechovirus, Picornavirus, Respiratory Syncytial Virus, Chlamydophila pneumoniae, Mycoplasma pneumoniae), two different bacterial PCR kits will be used to test each eluate (admission and discharge): the Fast Track Diagnostics (FTD) Bacterial pneumonia CAP (for Community Acquired Pneumonia) kit (Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella spp) and the FTD Bacterial pneumonia HAP (for Hospital Acquired Pneumonia) kit (Klebsiella pneumoniae, Pseudomonas aeruginosa).

The expenses of additional examinations will not be charged to the patient or to his health insurance company, but will be paid for by the HUG within the framework fixed price for hospitalization.

Evaluation criteria:

  • Assessments by the physician, before and after CT scanning, will be compared: number of upgraded or downgraded diagnoses; sensitivity and specificity of chest radiography RT and CT; correlation between the physician and the radiologist.
  • Descriptions of the etiologies of pneumonia, with number of viral and bacterial pneumonia.
  • Clinical, radiological, microbiological correlations.
  • Outcome (re-hospitalization, mortality) at 30 and 90 days.

Statistical considerations:

The investigators hypothesize that chest CT will upgrade the certainty of diagnosis in 19% of cases (14). To significantly increase the level of diagnosis of pneumonia, 46 patients with suspicion of pneumonia are needed (α = 0.05, β 0.1). The investigators estimate the rate of pneumonia in this population to be 45% (15); this implies that 100 participants should be enrolled in order to significantly increase the accuracy of diagnosis.

Inclusion in this study could begin in June 2015, for 12 months, with the last follow-up for the last patient coming after a total of 15 months (12 months plus 90 days).

Anticipated results:

The investigators anticipated that low-dose CT scan will improve the diagnosis of pneumonia in the elderly. The study's final objective is to prepare a second randomized study measuring the impact of chest CT scans on the management of patients in two cohorts of patients - one which only undergoes a chest X-ray, and one which only undergoes a CT scan - for assessing diagnosis and treatment.

Conditions
Pneumonia
Being tested
Low dose CT
Medical subject headings
Pneumonia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Low dose CTDevice

    Thoracic CT scan will be performed within the first 48-72 hours of admission, with an analysis and conclusion by a radiologist

Study groups in NCT02467192
Study groupRoleWhat they receive
Low dose CTExperimentalAll patients will have Thoracic CT scan
Receives: Device: Low dose CT

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Patients With Modified Diagnosis Probability After Low Dose CT (LDCT)

    Number and proportion of patients whose probability of pneumonia changed before and after LDCT : upgraded (increase of probability of pneumonia) or downgraded (decrease of probability of pneumonia)

    Measured: During the 24 hours after CT

Secondary outcomes (1)
  1. Number of Bacterial and Viral Pulmonary Infections

    Number of patients with viral pulmonary infection: patients with positive PCR for at least one virus in the naso- and oropharyngeal swab (NPS) performed at inclusion,

    Number of patients with bacterial infection: patients with positive PCR for a bacteria in the NPS at inclusion and/or with routine microbiologic methods (blood and sputum culture, urine antigen detection).

    Measured: At inclusion (during the first 72 hours after CT)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jun 2015 (estimated)
  2. Study start1 May 2015
  3. Primary completion1 May 2016
  4. Study completion1 May 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
203 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02467192
Sponsor's protocol ID
14-250
Acronym
PneumOldCT
Status last verified
Oct 2021
First submitted
27 May 2015
Last updated
2 Nov 2021
Data monitoring committee
No

Publications

  • Ulaj A, Ibsen A, Azurmendi L, Sanchez JC, Prendki V, Roux X. Improving prognostication of pneumonia among elderly patients: usefulness of suPAR. BMC Geriatr. 2024 Aug 24;24(1):709. doi: 10.1186/s12877-024-05270-0.

    PubMed 39182045
  • Hofmeister J, Garin N, Montet X, Scheffler M, Platon A, Poletti PA, Stirnemann J, Debray MP, Claessens YE, Duval X, Prendki V. Validating the accuracy of deep learning for the diagnosis of pneumonia on chest x-ray against a robust multimodal reference diagnosis: a post hoc analysis of two prospective studies. Eur Radiol Exp. 2024 Feb 2;8(1):20. doi: 10.1186/s41747-023-00416-y.

    PubMed 38302850
  • Prendki V, Huttner B, Marti C, Mamin A, Fubini PE, Meynet MP, Scheffler M, Montet X, Janssens JP, Reny JL, Kaiser L, Garin N, Stirnemann J. Accuracy of comprehensive PCR analysis of nasopharyngeal and oropharyngeal swabs for CT-scan-confirmed pneumonia in elderly patients: a prospective cohort study. Clin Microbiol Infect. 2019 Sep;25(9):1114-1119. doi: 10.1016/j.cmi.2018.12.037. Epub 2019 Jan 12.

    PubMed 30641227
  • Prendki V, Scheffler M, Huttner B, Garin N, Herrmann F, Janssens JP, Marti C, Carballo S, Roux X, Serratrice C, Serratrice J, Agoritsas T, Becker CD, Kaiser L, Rosset-Zufferey S, Soulier V, Perrier A, Reny JL, Montet X, Stirnemann J. Low-dose computed tomography for the diagnosis of pneumonia in elderly patients: a prospective, interventional cohort study. Eur Respir J. 2018 May 30;51(5):1702375. doi: 10.1183/13993003.02375-2017. Print 2018 May.

    PubMed 29650558

Questions about this trial

What is this clinical trial studying?

A study testing Low dose CT in people with Pneumonia, run by University Hospital, Geneva at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 2 Nov 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Patients With Modified Diagnosis Probability After Low Dose CT (LDCT) (time frame: During the 24 hours after CT). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02467192, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in